Pomerantz LLP Investigates Potential Securities Claims Against Viatris Inc.
New York, NY, March 17, 2025 – Pomerantz LLP, a leading securities law firm, is investigating potential securities claims on behalf of investors of Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS).
The investigation concerns whether Viatris and certain of its officers and/or directors have engaged in securities fraud, violating federal and state securities laws. The investigation comes following a series of revelations regarding the Company’s financial statements and business practices.
Background
Viatris is a global healthcare company formed through the merger of Mylan N.V. and Pfizer Inc.’s Upjohn business. The Company focuses on developing, manufacturing, and marketing a portfolio of branded and generic medicines.
Alleged Misrepresentations
According to reports, the Securities and Exchange Commission (SEC) is investigating Viatris for potential accounting irregularities. These reports suggest that the Company may have overstated its earnings by as much as $2 billion between 2019 and 2021.
Additionally, a whistleblower lawsuit filed in early 2025 alleges that Viatris engaged in a scheme to inflate its earnings by manipulating the timing of drug sales and recognizing revenue prematurely.
Effects on Investors
The potential misrepresentations could significantly impact investors who purchased Viatris securities during the relevant period. Such investors may have relied on the Company’s misstated financial statements and optimistic statements from management when making investment decisions.
If the allegations are proven, Viatris investors may be entitled to damages resulting from the Company’s securities law violations. Pomerantz LLP is encouraging investors with significant losses to contact the firm for a free consultation.
Effects on the World
The investigation into Viatris has far-reaching implications beyond the Company and its investors. The healthcare industry as a whole could face increased scrutiny, as regulators and the public demand greater transparency and accountability.
Additionally, the investigation could deter institutional investors from engaging in mergers and acquisitions, as the potential for hidden financial irregularities becomes a greater concern.
Conclusion
The potential securities fraud allegations against Viatris have significant implications for both the Company and its investors. As the investigation unfolds, it is important for investors to remain informed and seek professional guidance to protect their interests. Pomerantz LLP is dedicated to ensuring that investors receive the compensation they deserve.
- Pomerantz LLP is investigating potential securities claims against Viatris Inc.
- Investigation follows allegations of accounting irregularities and potential revenue manipulation
- Securities fraud could impact investors who purchased Viatris securities during the relevant period
- Industry-wide implications, including increased scrutiny and potential deterrence of mergers and acquisitions
- Pomerantz LLP encourages investors with significant losses to contact the firm for a free consultation
